Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Sang S, Datoo MS, Otieno E, Muiruri C, Bellamy D, Gathuri E, Ngoto O, Musembi J, Provstgaard-Morys S, Stockdale L, Aboagye J, Woods D, Lawrie A, Roberts R, Keter K, Kimani D, Ndungu F, Kapulu M, Njau I, Orindi B, Ewer KJ, Hill AVS, Bejon P, Hamaluba M. Sang S, et al. Among authors: ewer kj. Wellcome Open Res. 2023 Oct 12;8:450. doi: 10.12688/wellcomeopenres.19795.1. eCollection 2023. Wellcome Open Res. 2023. PMID: 38813551 Free PMC article.
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Li K, Dodds M, Spreng RL, Abraha M, Huntwork RHC, Dahora LC, Nyanhete T, Dutta S, Wille-Reece U, Jongert E, Ewer KJ, Hill AVS, Jin C, Hill J, Pollard AJ, Munir Alam S, Tomaras GD, Dennison SM. Li K, et al. Among authors: ewer kj. Front Immunol. 2023 Feb 16;14:1049673. doi: 10.3389/fimmu.2023.1049673. eCollection 2023. Front Immunol. 2023. PMID: 36875126 Free PMC article.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS; R21/Matrix-M Phase 3 Trial Group. Datoo MS, et al. Among authors: ewer kj. Lancet. 2024 Feb 10;403(10426):533-544. doi: 10.1016/S0140-6736(23)02511-4. Epub 2024 Feb 1. Lancet. 2024. PMID: 38310910 Free article. Clinical Trial.
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N, Topazian HM, Natama HM, Bellamy D, Traoré O, Somé MA, Rouamba T, Tahita MC, Bonko MDA, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo MS, Lopez FR, Charles GD, McCain K, Ouedraogo JB, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill AVS, Ewer KJ, Ghani AC, Winskill P. Schmit N, et al. Among authors: ewer kj. Lancet Infect Dis. 2024 May;24(5):465-475. doi: 10.1016/S1473-3099(23)00816-2. Epub 2024 Feb 8. Lancet Infect Dis. 2024. PMID: 38342107 Free article.
Early diagnosis of subclinical multidrug-resistant tuberculosis.
Richeldi L, Ewer K, Losi M, Hansell DM, Roversi P, Fabbri LM, Lalvani A. Richeldi L, et al. Among authors: ewer k. Ann Intern Med. 2004 May 4;140(9):709-13. doi: 10.7326/0003-4819-140-9-200405040-00010. Ann Intern Med. 2004. PMID: 15126254
112 results